Regeneron Pharmaceuticals Financial Model
Pharmaceuticals Company Financials Example (Free Excel Download)
Regeneron Pharmaceuticals is a fully integrated biotechnology company that discovers, develops, manufactures, and commercialises medicines for serious diseases.
professionals from Deloitte
Used by professionals from
About this model
This model projects Regeneron's sum-of-the-parts cash flows to determine its equity valuation, specifically answering whether the rapid growth of the Sanofi collaboration (Dupixent) and the transition to EYLEA HD can successfully offset the revenue erosion from EYLEA biosimilar competition.
Regeneron Pharmaceuticals is a fully integrated biotechnology company that discovers, develops, manufactures, and commercialises medicines for serious diseases. The company operates through a hybrid business model, generating revenue from direct product sales in the US and highly lucrative profit-sharing collaborations globally.
Business segments include:
- Net Product Sales (approx. 45% of revenue): Direct US sales of wholly owned or globally rights-acquired drugs.
- Sanofi Collaboration Revenue (approx. 37% of revenue): Profit-sharing from the commercialisation of antibodies, overwhelmingly driven by Dupixent.
- Bayer Collaboration Revenue (approx. 10% of revenue): Profit-sharing from ex-US sales of EYLEA.
- Other Revenue (approx. 8% of revenue): Royalties and milestone payments from various partners.
The company is heavily concentrated in the US for direct sales, while its collaboration revenues provide global exposure. Regeneron is an R&D-heavy, organic growth engine that relies on its proprietary VelociSuite platforms rather than serial M&A. Its competitive position is dominant in retinal diseases and immunology, though it currently faces intense competitive pressure in the ophthalmology space from Roche's Vabysmo and emerging biosimilars. Recent major events include the 2022 acquisition of global rights to the oncology drug Libtayo from Sanofi, a massive $7 billion ongoing manufacturing expansion, and the critical 2023/2024 rollout of EYLEA HD to defend its retinal franchise.
The downloadable Regeneron Pharmaceuticals financial model includes SEC-sourced historical financials, forecast assumptions, core operating schedules, and valuation outputs in an Excel workbook built for review and scenario analysis.
A turnkey financial model
Live formulas, no hardcoded values
Outputs are driven by live formulas, so the workbook updates from its assumptions instead of relying on hardcoded results.
All assumptions in one tab
Inputs are clearly marked in the Assumptions tab and separated from calculations, making it clear what to change and what to leave intact.
Statements always balancing
For integrated-statement models, the balance sheet, cash flow, and supporting schedules tie through properly.
Distinct schedules for clarity
Debt, working capital, taxes, and cash flow can get messy quickly. We group calculations in clear schedules, not across disconnected tabs.
No hidden macros or external links
There are no unexplained external workbook links or macros to undermine auditability or portability.
Changes flow through the model
Update a key driver and see the impact carry through the forecast, financing, and return outputs. We never use hardcoded numbers in formulas.
Historicals & AssumptionsRegeneron Pharmaceuticals financial modelCompany, Historicals & Assumptions used
Source: SEC EDGAR · values in USD
| Line item | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
| Revenue | $16.07B | $12.17B | $13.12B | $14.20B | $14.34B |
| Acquired in-process research and development | $48.0M | $255.1M | $186.1M | $101.0M | $124.1M |
| Operating income | $8.95B | $4.74B | $4.05B | $3.99B | $3.58B |
| Net income | $8.08B | $4.34B | $3.95B | $4.41B | $4.50B |
Forecast assumptions
Defaults used in the downloadable model. Forecast horizon: FY2026–FY2030.
See 8 moreSee less
How to build a detailed financial model for Regeneron Pharmaceuticals
A complete walkthrough of every driver, margin, working-capital input, and capital-allocation assumption used in the downloadable model.
Revenue Deep Dive
Net Product Sales (EYLEA Franchise)
- Segment name: Net Product Sales (EYLEA and EYLEA HD)
- Revenue driver formula: Patient Volume x Net Selling Price
- Historical growth rate: EYLEA HD is growing rapidly (36% in 2025), while legacy EYLEA is declining sharply (-27% in 2025). Combined franchise growth is slightly negative.
- Key growth levers and headwinds: The primary lever is successfully switching existing EYLEA patients to the longer-acting EYLEA HD. Headwinds include aggressive pricing pressure, loss of market share to compounded bevacizumab, and direct competition from Vabysmo and biosimilars.
- Pricing dynamics: Highly competitive and subject to payer rebates and affordability constraints.
- Revenue recognition notes: Recognised upon delivery to specialty distributors and wholesalers. Subject to quarter-end inventory fluctuations.
- Seasonality: Generally stable, though Q1 often sees slight weakness due to US insurance deductible resets.
Net Product Sales (Other Products)
- Segment name: Net Product Sales (Libtayo, Praluent, Evkeeza)
- Revenue driver formula: Patient Volume x Net Selling Price
- Historical growth rate: Libtayo is growing at 15-20% annually.
- Key growth levers and headwinds: Label expansions for Libtayo into new oncology indications (e.g., cutaneous squamous cell carcinoma).
- Pricing dynamics: Standard oncology and rare disease pricing models.
- Revenue recognition notes: Regeneron now records global net sales for Libtayo following the 2022 restructuring of the Sanofi agreement.
Sanofi Collaboration Revenue
- Segment name: Sanofi collaboration revenue
- Revenue driver formula: Global Dupixent Sales x Dupixent Operating Margin x Regeneron Profit Share Percentage
- Historical growth rate: 25-35% CAGR over the last 3 years.
- Key growth levers and headwinds: Driven entirely by Dupixent volume growth, label expansions (e.g., COPD, CSU), and geographic rollout.
- Pricing dynamics: Sanofi controls pricing; Regeneron simply receives a share of the resulting profits.
- Revenue recognition notes: Regeneron does NOT record Dupixent sales as revenue. It records its share of the collaboration profits. The profit share percentage increases as Regeneron's historical development balance is repaid (currently Regeneron receives an increased share of 20% of profits until the $3.1 billion development balance is cleared).
Bayer Collaboration Revenue
- Segment name: Bayer collaboration revenue
- Revenue driver formula: Ex-US EYLEA Sales x 50% Profit Split
- Historical growth rate: Flat to low single-digit decline.
- Key growth levers and headwinds: Ex-US regulatory approvals for EYLEA HD and European biosimilar penetration.
- Pricing dynamics: Subject to European and Japanese statutory pricing regulations.
- Revenue recognition notes: Bayer records the ex-US sales; Regeneron records its 50% share of the profits.
Cost Structure
Variable Costs / COGS
- Line-by-line breakdown: "Cost of goods sold" (for proprietary products) and "Cost of collaboration and contract manufacturing" (for products manufactured for partners).
- Gross margin range: 80-86% on net product sales (declined to 82% in 2025 due to inventory write-offs and manufacturing investments).
- Key input costs: Biologics manufacturing raw materials, fill-finish operations.
- How COGS scales with revenue: Step-function scaling based on facility utilisation. Contract manufacturing for Sanofi/Bayer is essentially a zero-margin pass-through that inflates the COGS line without generating gross profit.
Operating Expenses
- R&D: Exceptionally high, typically 40-45% of total revenue ($6.4 to $6.6 billion guided for 2026). It covers the VelociSuite platforms and massive late-stage clinical trials. Regeneron funds 100% of Libtayo R&D but shares other antibody R&D with Sanofi.
- SG&A: Typically 18-20% of revenue. Driven by US commercial sales forces for EYLEA and Libtayo.
- Depreciation & Amortisation: Embedded in operating expenses, growing due to recent heavy capex cycles.
- Stock-Based Compensation: Material, typically 5-7% of revenue, heavily utilised to retain scientific talent.
- Restructuring / one-time charges: Rare, though acquired In-Process R&D (IPR&D) charges occur occasionally from licensing deals (e.g., Tessera Therapeutics).
Margin Profile
- Gross margin: 82% (GAAP, on net product sales).
- Operating margin: 25-30%.
- Net margin: 30-32% (boosted by high-margin collaboration revenue and interest income on large cash balances).
- Margin trend: Operating margins have compressed slightly as R&D spending accelerates to rebuild the pipeline ahead of the EYLEA patent cliff.
Balance Sheet Structure
- Total assets: Approximately $30-35 billion.
- Key asset categories: Cash and marketable securities (often exceeding $10 billion), Receivables from collaborators (Sanofi/Bayer), and PP&E.
- Goodwill & intangibles as % of total assets: Very low (under 5%), reflecting the organic R&D business model rather than M&A.
- Working capital profile:
- DSO: 45-55 days.
- DIO: 150-180 days (biologics require long manufacturing lead times).
- DPO: 30-40 days.
- Net working capital: Positive, driven by massive cash balances and receivables from highly rated pharmaceutical partners.
- PP&E: Expanding rapidly. Driven by a $2 billion investment in Saratoga Springs and other New York/North Carolina facilities.
- Right-of-use assets: Immaterial relative to the cash and PP&E balances.
Capital Expenditure & Investment
- Capex as % of revenue: 6-7% (historically high for biotech, running $850 million to $975 million annually).
- Maintenance capex vs. growth capex: 20% maintenance, 80% growth (new fill-finish facilities and biologics manufacturing).
- Major capex programmes: Rensselaer fill/finish facility validation and Saratoga Springs expansion.
- Capitalised software: Immaterial.
- M&A pattern: Organic grower. Prefers licensing deals and early-stage partnerships over commercial-stage acquisitions.
Debt & Capital Structure
- Total debt: Approximately $1.98 billion in long-term debt.
- Net debt: Deeply negative (company has a massive net cash position).
- Debt/EBITDA ratio: Near zero.
- Key debt instruments: Senior unsecured notes.
- Maturity profile: Well-laddered with no near-term liquidity concerns.
- Interest rate profile: Fixed-rate bonds.
- Share repurchase programme: Highly active. A new $3.0 billion programme was authorised in February 2025.
- Dividend policy: Initiated a quarterly cash dividend in 2025 ($0.88 per share for March 2025, yielding under 1%).
Cash Flow Characteristics
- Operating cash flow conversion: >1.0x. Collaboration revenues are highly cash-generative as they represent pure profit share without associated manufacturing working capital drag.
- Free cash flow margin: 25-30%, temporarily suppressed by the peak capex cycle.
- Major non-cash items: Stock-based compensation, acquired IPR&D charges, and depreciation.
- Working capital cash flow impact: Generally a use of cash as inventory builds for new product launches (EYLEA HD).
- Cash tax rate vs. GAAP effective tax rate: GAAP ETR is typically 13-15%, benefiting from US R&D tax credits and the FDII (Foreign-Derived Intangible Income) deduction.
Sheet Structure
- Assumptions: Hardcoded drivers for EYLEA volume transition, Dupixent global sales estimates, profit share percentages, and margin guidance.
- Revenue Build: Detailed schedules for Net Product Sales (split by EYLEA HD, EYLEA, Libtayo, Praluent, Evkeeza), Sanofi Collaboration Revenue (driven by Dupixent global sales), Bayer Collaboration Revenue, and Other Revenue.
- Income Statement: Mirrors the 10-K exactly. Must separate "Cost of goods sold" from "Cost of collaboration and contract manufacturing". Must show R&D and SG&A net of collaborator reimbursements.
- Balance Sheet: Standard biotech layout. Must include specific lines for "Receivables from Sanofi and Bayer" and "Deferred revenue".
- Cash Flow Statement: Indirect method starting from Net Income. Must explicitly model share repurchases and the newly initiated dividend.
- Debt & Equity Schedule: Tracks the $1.98 billion debt, interest income on the massive cash balance, and the $3.0 billion share repurchase authorisation depletion.
- DCF Valuation: Unlevered free cash flow build, WACC calculation, and terminal value based on pipeline probability weighting.
Key Financial Relationships
- `Total EYLEA Franchise US Sales = EYLEA US Sales + EYLEA HD US Sales`
- `Dupixent Profit Share = Global Dupixent Sales (recorded by Sanofi) * Dupixent Operating Margin * Regeneron Profit Split %`
- `Sanofi Collaboration Revenue = Dupixent Profit Share + Other Sanofi Antibody Profits`
- `Bayer Collaboration Revenue = Ex-US EYLEA Sales (recorded by Bayer) * 50%`
- `Total Revenues = Net Product Sales + Sanofi Collaboration Revenue + Bayer Collaboration Revenue + Other Revenue`
- `Gross Profit on Net Product Sales = Net Product Sales - Cost of Goods Sold` (Note: Exclude Cost of collaboration and contract manufacturing from this specific metric).
- `Reported R&D Expense = Gross R&D Spend - R&D Reimbursements from Collaborators`
- `Reported SG&A Expense = Gross SG&A Spend - SG&A Reimbursements from Collaborators`
- `Interest Income = Average Cash & Marketable Securities Balance * Yield on Cash`
- `Shares Outstanding = Prior Period Shares - (Share Repurchase Spend / Average Share Price)`
Cross-Sheet Dependencies
- The Revenue Build is the critical chain. Dupixent global sales assumptions feed the Sanofi Collaboration Revenue line, which feeds the Income Statement.
- The Income Statement generates Net Income, which flows to the top of the Cash Flow Statement.
- The Cash Flow Statement dictates the ending Cash balance on the Balance Sheet.
- The Cash balance on the Balance Sheet feeds the Debt & Equity Schedule to calculate Interest Income, which loops back to the Income Statement. (This is a circular reference that requires a toggle switch to break).
Sign Convention
- Revenues, Assets, and Equity are entered as positive numbers.
- Expenses (COGS, R&D, SG&A) are entered as positive numbers in their specific build schedules but subtracted in the Income Statement totals.
- Cash Flow Statement: Cash inflows (e.g., Net Income, Depreciation) are positive. Cash outflows (e.g., Capex, Share Repurchases, Dividends) are negative.
Things Most Likely to Go Wrong
- Sanofi Revenue Misinterpretation: The builder might try to forecast Dupixent sales and add them directly to Regeneron's top line. Regeneron only records its share of the profits. Dupixent sales must be modeled off-sheet and multiplied by the profit-share percentage.
- Expense Netting Error: Since the 2020 accounting change, Sanofi and Bayer reimbursements for R&D and SG&A are netted against the respective expense lines. The builder must not record these reimbursements as revenue.
- EYLEA Double Counting: When modeling the EYLEA franchise, the builder must ensure that EYLEA HD growth is cannibalising legacy EYLEA volume. If both are modeled with positive independent growth rates, the US retinal market size will be grossly overstated.
- Contract Manufacturing Margin: The "Cost of collaboration and contract manufacturing" line is essentially a pass-through. The builder must not apply the company's 82% gross margin to this revenue stream.
- Libtayo Global Rights: Historical data before July 2022 only shows US Libtayo sales. The model must reflect that Regeneron now records global net sales for Libtayo.
- Development Balance Repayment: Regeneron's share of Sanofi antibody profits is currently elevated (20% instead of 10% for the repayment portion) until the $3.1 billion development balance is cleared. The model must track this balance and step down the profit share once fully repaid.
- Share Count Reduction: Regeneron aggressively buys back stock. Failing to model the shrinking share count will artificially depress EPS forecasts.
- Dividend Initiation: The company just started paying a dividend in 2025. Historical models will not have this cash outflow; the builder must add it.
Validation Checks
- "Sanofi Collaboration Revenue should be 35-40% of Total Revenue; flag if outside this band."
- "Gross margin on Net Product Sales should be in the 79-84% range based on 2026 guidance; flag if outside."
- "Combined EYLEA + EYLEA HD US sales growth should be between -5% and +5% (franchise is mature and defending share, not a high-growth asset)."
- "R&D expense must be >40% of Total Revenue; flag if the model assumes unrealistic operating leverage here."
- "Balance sheet must balance: Total Assets = Total Liabilities + Equity in every period."
- "Effective tax rate should be 13-15%; flag if it reverts to the statutory 21% rate."
- "Capex should be between $850 million and $975 million for the near-term forecast periods based on management guidance."
Key Assumptions (Default Values)
| Assumption | Default Value | Unit | Rationale |
|---|---|---|---|
| EYLEA HD US Sales Growth | 30.0 | % | Rapid uptake and transition of existing patients (based on 36% growth in 2025). |
| EYLEA Legacy US Sales Growth | -25.0 | % | Managed decline due to EYLEA HD cannibalisation and biosimilar/Vabysmo competition. |
| Dupixent Global Sales Growth | 20.0 | % | Continued strong uptake in immunology, COPD, and CSU indications. |
| Sanofi Collab Revenue / Dupixent Sales | 29.0 | % | Implied blended profit share and royalty capture rate based on 2025 actuals. |
| Gross Margin (Net Product Sales) | 80.0 | % | Midpoint of management's 2026 GAAP guidance (79-80%). |
| R&D Expense (GAAP) | 6,565 | $ Millions | Midpoint of management's 2026 guidance ($6.45B - $6.68B). |
| SG&A Expense (GAAP) | 2,950 | $ Millions | Midpoint of management's 2026 guidance ($2.86B - $3.04B). |
| Capex | 912.5 | $ Millions | Midpoint of management's 2025/2026 facility expansion guidance ($850M - $975M). |
| Effective Tax Rate | 14.0 | % | Historical average benefiting from R&D credits and FDII. |
| Annual Dividend per Share | 3.52 | $ | Based on newly initiated $0.88 quarterly dividend in 2025. |
| Share Repurchase Annual Spend | 1,500 | $ Millions | Run-rate based on the new $3.0 billion authorisation. |
| WACC | 8.5 | % | Standard discount rate for large-cap, commercial-stage biotechnology. |
| Terminal Growth Rate | 1.5 | % | Conservative long-term growth assuming pipeline replaces patent expirations. |
Data Sources & Benchmarks
- Filings: SEC EDGAR (Regeneron 10-K, 10-Q, 8-K), Regeneron Investor Relations page.
- Key Peers: Amgen (AMGN), Vertex Pharmaceuticals (VRTX), Gilead Sciences (GILD), Biogen (BIIB).
- Industry Data: IQVIA for US prescription volume data (critical for tracking the EYLEA to EYLEA HD transition week-by-week).
- Consensus Estimates: Bloomberg or FactSet for Dupixent global sales consensus (since Sanofi reports this, tracking Sanofi consensus is required to model Regeneron).
Sources
- Regeneron Pharmaceuticals Q4 and Full Year 2025 Earnings Press Release (January 30, 2026)
- Regeneron Pharmaceuticals 2025 Form 10-K
- Regeneron Pharmaceuticals Change in Accounting Presentation FAQ (April 2020)
- Regeneron Investor Relations: Sanofi Antibody Collaboration Accounting Post Libtayo Transaction Presentation
Do more with the Regeneron Pharmaceuticals model
Frequently asked
What does Regeneron Pharmaceuticals do?+
Regeneron Pharmaceuticals is a fully integrated biotechnology company that discovers, develops, manufactures, and commercializes medicines for serious diseases. The company operates through a hybrid business model, generating revenue from direct product sales in the US and highly lucrative profit-sharing collaborations globally.
How does Regeneron Pharmaceuticals generate its revenue?+
Regeneron generates revenue primarily through Net Product Sales in the US and significant profit-sharing collaborations. The Sanofi Collaboration, largely driven by Dupixent, accounts for approximately 37% of revenue, while the Bayer Collaboration contributes about 10% from ex-US EYLEA sales.
What are Regeneron's capital expenditure trends?+
Regeneron's capital expenditure is historically high for a biotech company, running between $850 million and $975 million annually, representing 6-7% of revenue. Approximately 80% of this capex is growth-related, driven by significant investments in new fill-finish facilities and biologics manufacturing expansions.
What is Regeneron's working capital profile?+
Regeneron maintains a positive net working capital, primarily due to substantial cash balances and receivables from highly rated pharmaceutical partners. The company has a DIO of 150-180 days due to long biologics manufacturing lead times, while DSO is 45-55 days and DPO is 30-40 days.
What is the primary purpose of the Regeneron financial model?+
The Regeneron financial model projects the company's sum-of-the-parts cash flows to determine its equity valuation. Specifically, it assesses whether the rapid growth from the Sanofi collaboration (Dupixent) and the transition to EYLEA HD can successfully counteract revenue erosion from EYLEA biosimilar competition.
Can I download an Excel financial model for Regeneron Pharmaceuticals?+
Yes, a downloadable Excel financial model is available for Regeneron Pharmaceuticals (REGN). This general corporate model forecasts the company's financials from FY2026 to FY2030, incorporating key assumptions like revenue growth and margin percentages.
Have more financial modelling questions? Contact us
Created by ex-finance professionals
Hey, I’m Alex and I created Finamodel.
Over my years in the finance industry I kept building the same models over and over again. Same structure, same assumptions, different logo. So I started building frameworks to turn them into clean, reusable templates.
Every model here is one I’d actually use for a client, and I personally vet each one before it goes up.
I’m not an expert in every industry, but I’ve built enough models to know what belongs in one. And when something is completely foreign to me, I reach out to my network for experts to work on our models with us.
Having a template library on hand cuts a first build from hours to minutes.
Need help finding your model? You’ll find me in the Finamodel app!
Other Pharmaceuticals Company Financial Models
Browse another company in the same sector.
AbbVie
AbbVie is a global, research-based biopharmaceutical company that discovers and delivers innovative medicines and aesthetic products.
Amgen
Amgen discovers, develops, manufactures, and delivers innovative human therapeutics, focusing on areas of high unmet medical need.
Biogen
Biogen is a global biotechnology company that discovers, develops, and delivers therapies for neurological, immunological, and rare diseases, including multiple sclerosis and Alzheimer's treatments.
Bristol Myers Squibb
Bristol Myers Squibb (BMS) is a global biopharmaceutical company focused on discovering, developing, and delivering innovative medicines for patients with serious diseases.
Gilead Sciences
Gilead Sciences is a research-based biopharmaceutical company that discovers, develops, and commercialises innovative medicines in areas of unmet medical need.
Incyte
Incyte Corporation is a global commercial-stage biopharmaceutical company focused on the discovery, development, and commercialisation of proprietary therapeutics, primarily in haematology, oncology, and inflammation and autoimmunity (IAI).
Johnson & Johnson
Johnson & Johnson is a diversified global healthcare leader engaged in the research, development, manufacture, and sale of pharmaceutical products and medical devices.
Lilly (Eli)
Eli Lilly is a global pharmaceutical company that discovers, develops, manufactures, and markets human medicines, with a dominant focus on cardiometabolic diseases, oncology, immunology, and neuroscience.
Explore more Healthcare financial model templates.
